|The following article is part of conference coverage from the 2018 Genitourinary Cancers Symposium in San Francisco. Renal and Urology News’ staff will be reporting live on medical studies conducted by urologists and other specialists who are tops in their field in kidney stones, prostate cancer, kidney cancer, bladder cancer, enlarged prostate, and more. Check back for the latest news from GU 2018.|
SAN FRANCISCO—A negative confirmatory prostate biopsy is associated with a significantly lower rate of progression to treatment among prostate cancer (PCa) patients on active surveillance (AS), investigators reported at the 2018 Genitourinary Cancers Symposium.
In a retrospective study, Keyan Salari, MD, of Massachusetts General Hospital in Boston, and colleagues identified 974 men enrolled in AS from 1997 to 2014 who had a minimum follow-up of 6 months. Of these, 101 had a negative confirmatory biopsy and 169 had a positive confirmatory biopsy. The investigators considered biopsy results containing only benign prostatic tissue, prostatic intraepithelial neoplasia (PIN), or atypical small acinar proliferation (ASAP) to be negative.
The patients in the negative and positive biopsy groups had a median age of 63 and 65 years, respectively.
On multivariate analysis, a negative versus a positive confirmatory biopsy was associated with a 65% decreased risk of progressing to treatment. Confirmatory biopsy status not associated with risk of adverse pathologic features at the time of radical prostatectomy and metastasis-free, disease-specific, or overall survival, according to the investigators.
“A negative confirmatory biopsy is associated with a significantly lower rate of progression to definitive treatment,” the authors concluded in their poster. “Confirmatory biopsy status may serve as a useful tool for patient counseling and for determining the frequency of subsequent biopsies for men on AS.”
Salari K, Zlatev DV, Kuppermann D, et al. The prognostic impact of a negative confirmatory biopsy in men on active surveillance for prostate cancer. Data presented at the 2018 Genitourinary Cancers Symposium, held in San Francisco Feb. 8–10. Abstract 76.